113 filings
Page 4 of 6
8-K
2i1a83t ky
31 Jul 20
Submission of Matters to a Vote of Security Holders
8:43am
8-K
wwqvf6pi5
28 Jul 20
Novan President and CEO, Paula Brown Stafford Named Chairman of the Board
8:09am
8-K
u4o2sx8ahvojnzsgeym
22 Jul 20
Entry into a Material Definitive Agreement
7:05am
8-K
ra4d4
16 Jul 20
Termination of a Material Definitive Agreement
4:45pm
8-K
05b 8n6r8ek1
9 Jul 20
Other Events
4:45pm
8-K
4gq57xuio7xflfayo
25 Jun 20
Novan Anticipates Current Cash Position Provides Sufficient Capital to Conduct Additional SB206 Phase 3 Pivotal Trial
8:07am
8-K
z3b2h 8sh2zg
16 Jun 20
Entry into a Material Definitive Agreement
9:44pm
8-K
q417z
15 May 20
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
8:01am
8-K
qeiv3j
23 Apr 20
Entry into a Material Definitive Agreement
4:49pm
8-K
hknr15q qoltjpg7b
3 Apr 20
Novan Receives Verbal Guidance from FDA for SB206 and Announces Sato Program Advancement
8:21am
8-K
a21e swijst
26 Mar 20
Entry into a Material Definitive Agreement
4:16pm
8-K
87dfyki
23 Mar 20
Novan Announces Data from B-SIMPLE Week 24 Safety Evaluation and COVID-19 Business Updates
8:20am
8-K
xlb2v
3 Mar 20
Entry into a Material Definitive Agreement
4:18pm
8-K
u185g
6 Feb 20
Novan Provides SB206 Program and Business Update
8:36am
8-K
6a3wxwm nvgr
4 Feb 20
Departure of Directors or Certain Officers
4:17pm
8-K
8cr7ud3
3 Jan 20
Novan Reports Top-Line Efficacy Results from Phase 3 Trials of SB206 for Molluscum Contagiosum
8:13am
8-K
bwc3 1yh0s9w5h8msz4
18 Dec 19
Novan Announces Planned Chief Executive Officer Transition
8:05am
8-K
2bs6vtncxqm zvzd
5 Sep 19
Novan and Aspire Capital Enter into a Common Stock Purchase Agreement for up to $25 Million
6:36am
8-K
jjp89uiys9320ulam
6 Aug 19
Departure of Directors or Certain Officers
4:34pm
8-K
v3i g53c9
9 May 19
Novan Completes Funding Transaction with Ligand Pharmaceuticals
4:17pm